Fresenius Medical Care


Advancing in kidney care

11/07/19 -"The US government’s announcement has brought some clarity about how care might be provided in the future. As administration is involved, it still seems to be a long time before implementation. ..."

Pages
45
Language
English
Published on
11/07/19
You may also be interested by these reports :
11/11/19
Sales in Q3 were strong, led by broad-based growth across regions and channels in the Hearing and Audio segments. But, the EBITA margin was down 10bp ...

05/11/19
Coloplast reported mixed Q4 19 numbers – in line revenue and a miss on the bottom-line. Sales were up 8% on an organic basis, led by strong growth in ...

04/11/19
We have made some first adjustments to our expectations as we still see 2020 as a kind of transition year. Despite some strong and profitable ...

04/11/19
...has been ‘bought’ by lower profitability. Management confessed that it had underestimated the costs and the development of the learning curve. ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO